AKRO250117P30000
- 5.00
- +2.25+81.82%
Akero Therapeutics Newsroom
Akero Therapeutics Analyst Ratings
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
Promising Developments in Akero Therapeutics' EFX Fuel Buy Rating With $50 Price Target
BofA Securities Maintains Akero Therapeutics(AKRO.US) With Hold Rating, Maintains Target Price $35
Positive Outlook for Akero Therapeutics Based on Promising Clinical Trial Developments
Express News | Akero Therapeutics Inc - Data From Synchrony Real-World Study Expected in H1 2026
Express News | Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 Synchrony Real-World Study Evaluating Efruxifermin (Efx) in Patients With Non-Invasively Diagnosed Mash or Masld
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients With Non-Invasively Diagnosed MASH or MASLD
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Akero Therapeutics Insider Sold Shares Worth $280,330, According to a Recent SEC Filing
BofA Securities Maintains Akero Therapeutics(AKRO.US) With Hold Rating, Announces Target Price $35
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38
Possible Bearish Signals With Akero Therapeutics Insiders Disposing Stock
Insider Sale: Senior VP of $AKRO (AKRO) Sells 925 Shares
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment
Akero a New Buy at Citi on Liver Disease Asset
Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup
Promising Potential of Akero Therapeutics' Efruxifermin Highlighted by Positive Phase 2b HARMONY Study Results
Akero Therapeutics (AKRO) Receives a Buy From Phillip Securities